Compare Cadila Healthcare with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs AUROBINDO PHARMA - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE AUROBINDO PHARMA CADILA HEALTHCARE/
AUROBINDO PHARMA
 
P/E (TTM) x 34.3 19.6 175.3% View Chart
P/BV x 6.0 4.2 142.0% View Chart
Dividend Yield % 0.6 0.2 230.9%  

Financials

 CADILA HEALTHCARE   AUROBINDO PHARMA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-20
AUROBINDO PHARMA
Mar-19
CADILA HEALTHCARE/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs352830 42.4%   
Low Rs207527 39.2%   
Sales per share (Unadj.) Rs139.2333.9 41.7%  
Earnings per share (Unadj.) Rs11.840.4 29.2%  
Cash flow per share (Unadj.) Rs18.651.8 35.9%  
Dividends per share (Unadj.) Rs3.502.50 140.0%  
Dividend yield (eoy) %1.30.4 340.0%  
Book value per share (Unadj.) Rs101.4237.1 42.7%  
Shares outstanding (eoy) m1,023.74585.91 174.7%   
Bonus / Rights / Conversions -ESOP-  
Price / Sales ratio x2.02.0 98.8%   
Avg P/E ratio x23.716.8 141.2%  
P/CF ratio (eoy) x15.013.1 114.8%  
Price / Book Value ratio x2.82.9 96.3%  
Dividend payout %29.86.2 480.2%   
Avg Mkt Cap Rs m286,033397,569 71.9%   
No. of employees `00013.417.9 75.1%   
Total wages/salary Rs m24,14525,849 93.4%   
Avg. sales/employee Rs Th10,632.710,956.9 97.0%   
Avg. wages/employee Rs Th1,801.21,447.7 124.4%   
Avg. net profit/employee Rs Th898.51,324.3 67.8%   
INCOME DATA
Net Sales Rs m142,531195,636 72.9%  
Other income Rs m1,1391,553 73.3%   
Total revenues Rs m143,670197,189 72.9%   
Gross profit Rs m24,19839,519 61.2%  
Depreciation Rs m6,9656,680 104.3%   
Interest Rs m3,4182,626 130.2%   
Profit before tax Rs m14,95431,767 47.1%   
Minority Interest Rs m28827 1,066.7%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-881 0.0%   
Tax Rs m3,1987,269 44.0%   
Profit after tax Rs m12,04423,645 50.9%  
Gross profit margin %17.020.2 84.0%  
Effective tax rate %21.422.9 93.5%   
Net profit margin %8.512.1 69.9%  
BALANCE SHEET DATA
Current assets Rs m87,154153,645 56.7%   
Current liabilities Rs m82,694120,429 68.7%   
Net working cap to sales %3.117.0 18.4%  
Current ratio x1.11.3 82.6%  
Inventory Days Days71135 52.8%  
Debtors Days Days9464 147.3%  
Net fixed assets Rs m133,236103,909 128.2%   
Share capital Rs m1,024586 174.8%   
"Free" reserves Rs m102,733138,322 74.3%   
Net worth Rs m103,757138,908 74.7%   
Long term debt Rs m32,1461,800 1,786.4%   
Total assets Rs m236,866264,544 89.5%  
Interest coverage x5.413.1 41.0%   
Debt to equity ratio x0.30 2,391.6%  
Sales to assets ratio x0.60.7 81.4%   
Return on assets %6.59.9 65.7%  
Return on equity %11.617.0 68.2%  
Return on capital %13.723.8 57.6%  
Exports to sales %049.6 0.0%   
Imports to sales %018.8 0.0%   
Exports (fob) Rs mNA97,091 0.0%   
Imports (cif) Rs mNA36,741 0.0%   
Fx inflow Rs m52,75297,316 54.2%   
Fx outflow Rs m14,50440,589 35.7%   
Net fx Rs m38,24856,727 67.4%   
CASH FLOW
From Operations Rs m25,05416,220 154.5%  
From Investments Rs m-10,123-28,768 35.2%  
From Financial Activity Rs m-10,94219,191 -57.0%  
Net Cashflow Rs m3,9896,656 59.9%  

Share Holding

Indian Promoters % 74.8 54.1 138.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 8.0 104.4%  
FIIs % 5.9 27.7 21.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 10.2 107.8%  
Shareholders   44,069 69,601 63.3%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   STERLING BIOTECH  FULFORD INDIA  DR. REDDYS LAB  AJANTA PHARMA  UNICHEM LAB  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Extend Gains; Bajaj Auto & Bajaj Finance Surge 4%(12:30 pm)

Share markets in India are presently trading on a strong note, tracking gains in global peers.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 40.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

Is Intraday Trading For You?(Fast Profits Daily)

May 13, 2021

Do you think you have what it takes to be an intraday trader? Find out in this video.

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


May 18, 2021 01:41 PM

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 5-YR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS